Haematologica (Dec 2008)

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

  • Francesca Palandri,
  • Fausto Castagnetti,
  • Nicoletta Testoni,
  • Simona Luatti,
  • Giulia Marzocchi,
  • Simona Bassi,
  • Massimo Breccia,
  • Giuliana Alimena,
  • Ester Pungolino,
  • Giovanna Rege-Cambrin,
  • Riccardo Varaldo,
  • Maurizio Miglino,
  • Giorgina Specchia,
  • Eliana Zuffa,
  • Felicetto Ferrara,
  • Monica Bocchia,
  • Giuseppe Saglio,
  • Fabrizio Pane,
  • Daniele Alberti,
  • Giovanni Martinelli,
  • Michele Baccarani,
  • Gianantonio Rosti

DOI
https://doi.org/10.3324/haematol.13068
Journal volume & issue
Vol. 93, no. 12

Abstract

Read online

Background Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival. However, few long-term data, based on large, prospective and controlled trials are available on the outcome of these patients.Design and Methods We conducted a phase II trial of imatinib 600 mg daily in patients with chronic myeloid leukemia in blast crisis. The return to chronic phase was defined as